Eritus Syrup is a combination pharmaceutical formulation containing Terbutaline (1.25 mg/5 ml), Acebrophylline (50 mg/5 ml), and Guaifenesin (50 mg/5 ml), designed to provide symptomatic relief in respiratory conditions characterized by bronchospasm, mucus hypersecretion, and airway obstruction. Terbutaline, a selective beta-2 adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscle, thereby improving airflow and reducing wheezing and breathlessness. Acebrophylline, a xanthine derivative, exhibits bronchodilator and mucoregulatory properties, facilitating the clearance of mucus and reducing inflammation in the airways. Guaifenesin functions as an expectorant, promoting the liquefaction and expectoration of mucus, which aids in relieving chest congestion. The synergistic action of these active ingredients makes Eritus Syrup effective in managing conditions such as chronic bronchitis, asthma, and other obstructive airway diseases. It is indicated for patients requiring both bronchodilation and enhanced mucus clearance. Eritus Syrup should be used under medical supervision, with dosage adjusted according to the severity of symptoms and patient response. Caution is advised in patients with cardiovascular disorders, hypertension, and hypersensitivity to any component. Common side effects may include tremors, headache, and gastrointestinal discomfort.